Literature DB >> 10098755

A high incidence of vertebral fracture in women with breast cancer.

J A Kanis1, E V McCloskey, T Powles, A H Paterson, S Ashley, T Spector.   

Abstract

Because treatment for breast cancer may adversely affect skeletal metabolism, we investigated vertebral fracture risk in women with non-metastatic breast cancer. The prevalence of vertebral fracture was similar in women at the time of first diagnosis to that in an age-matched sample of the general population. The incidence of vertebral fracture, however, was nearly five times greater than normal in women from the time of first diagnosis [odds ratio (OR), 4.7; 95% confidence interval (95% CI), 2.3-9.9], and 20-fold higher in women with soft-tissue metastases without evidence of skeletal metastases (OR, 22.7; 95% CI, 9.1-57.1). We conclude that vertebral fracture risk is markedly increased in women with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098755      PMCID: PMC2362233          DOI: 10.1038/sj.bjc.6690188

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.

Authors:  G J Powell; J Southby; J A Danks; R G Stillwell; J A Hayman; M A Henderson; R C Bennett; T J Martin
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

2.  Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.

Authors:  T Saarto; C Blomqvist; M Välimäki; P Mäkelä; S Sarna; I Elomaa
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

3.  Assessment of response and recurrence in breast cancer.

Authors:  J L Hayward; J W Meakin; H J Stewart
Journal:  Semin Oncol       Date:  1978-12       Impact factor: 4.929

4.  Clodronate decreases the frequency of skeletal metastases in women with breast cancer.

Authors:  J A Kanis; T Powles; A H Paterson; E V McCloskey; S Ashley
Journal:  Bone       Date:  1996-12       Impact factor: 4.398

5.  Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.

Authors:  T Taube; I Elomaa; C Blomqvist; M N Beneton; J A Kanis
Journal:  Bone       Date:  1994 Mar-Apr       Impact factor: 4.398

6.  Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial.

Authors:  P Filipponi; S Cristallini; E Rizzello; G Policani; L Fedeli; F Gregorio; S Boldrini; S Troiani; C Massoni
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

7.  Risk of osteoporotic fractures in women with breast cancer: a population-based cohort study.

Authors:  J P Utz; L J Melton; S H Kan; B L Riggs
Journal:  J Chronic Dis       Date:  1987

8.  Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: the Chingford Study.

Authors:  T D Spector; E V McCloskey; D V Doyle; J A Kanis
Journal:  J Bone Miner Res       Date:  1993-07       Impact factor: 6.741

  8 in total
  74 in total

1.  Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

Authors:  R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

Review 2.  Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses.

Authors:  Canan P Fornusek; Sharon L Kilbreath
Journal:  J Cancer Surviv       Date:  2017-06-21       Impact factor: 4.442

3.  Is there an association between high heparanase level and osteoporosis risk in breast cancer patients without clinical evidence of bone metastases?

Authors:  Kadri Altundag; Ozden Altundag; Mauricio Z Baptista; Selahattin Turen; Mustafa A Atik
Journal:  Osteoporos Int       Date:  2005-12       Impact factor: 4.507

4.  Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.

Authors:  Beatrice J Edwards; Dennis W Raisch; Veena Shankaran; June M McKoy; William Gradishar; Andrew D Bunta; Athena T Samaras; Simone N Boyle; Charles L Bennett; Dennis P West; Theresa A Guise
Journal:  Clin Cancer Res       Date:  2011-02-01       Impact factor: 12.531

5.  The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels.

Authors:  Luke J Peppone; Aaron S Rickles; Michelle C Janelsins; Michael R Insalaco; Kristin A Skinner
Journal:  Ann Surg Oncol       Date:  2012-03-24       Impact factor: 5.344

6.  Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.

Authors:  Stephanie L Hines; Betty Anne Mincey; Jeff A Sloan; Sachdev P Thomas; Elaine Chottiner; Charles L Loprinzi; Mark D Carlson; Pamela J Atherton; Muhammad Salim; Edith A Perez
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study.

Authors:  Luke J Peppone; Karen M Mustian; Randy N Rosier; Jennifer K Carroll; Jason Q Purnell; Michelle C Janelsins; Gary R Morrow; Supriya G Mohile
Journal:  Support Care Cancer       Date:  2013-09-17       Impact factor: 3.603

8.  Aromatase inhibitors-induced bone loss in early breast cancer.

Authors:  Jean-Jacques Body
Journal:  Bonekey Rep       Date:  2012-10-03

Review 9.  The expanding use of third-generation aromatase inhibitors: what the general internist needs to know.

Authors:  Susan Hong; Aarati Didwania; Olufunmilayo Olopade; Pamela Ganschow
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

10.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.